Salivary Gland Cancer - Pipeline Review, H2 2016

  • ID: 3961126
  • Drug Pipelines
  • 104 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Ignyta, Inc.
  • Johnson & Johnson
  • Loxo Oncology, Inc.
  • Merck & Co., Inc.
  • Plexxikon Inc.
  • MORE
Salivary Gland Cancer - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Salivary Gland Cancer – Pipeline Review, H2 2016, provides an overview of the Salivary Gland Cancer (Oncology) pipeline landscape.

Salivary gland cancer is a rare form of cancer that begins in the salivary glands. Salivary gland cancer can begin in any of the salivary glands in mouth, neck or throat. Symptoms include a lump or swelling on or near jaw or in neck or mouth, numbness in part of face, difficulty swallowing and trouble opening mouth widely. Risk factors include age and radiation exposure.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Salivary Gland Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Salivary Gland Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Salivary Gland Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.Salivary Gland Cancer.

Salivary Gland Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Salivary Gland Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Salivary Gland Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Salivary Gland Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Salivary Gland Cancer (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Salivary Gland Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Salivary Gland Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Ignyta, Inc.
  • Johnson & Johnson
  • Loxo Oncology, Inc.
  • Merck & Co., Inc.
  • Plexxikon Inc.
  • MORE
Introduction

Salivary Gland Cancer Overview

Therapeutics Development

Pipeline Products for Salivary Gland Cancer - Overview

Pipeline Products for Salivary Gland Cancer - Comparative Analysis

Salivary Gland Cancer - Therapeutics under Development by Companies

Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes

Salivary Gland Cancer - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Salivary Gland Cancer - Products under Development by Companies

Salivary Gland Cancer - Products under Investigation by Universities/Institutes

Salivary Gland Cancer - Companies Involved in Therapeutics Development

Bayer AG

Ignyta, Inc.

Johnson & Johnson

Loxo Oncology, Inc.

Merck & Co., Inc.

Plexxikon Inc.

Taiwan Liposome Company, Ltd.

Salivary Gland Cancer - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Cellular Immunotherapy for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

entrectinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LOXO-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pembrolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

regorafenib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tipifarnib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLC-388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target WT1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Salivary Gland Cancer - Dormant Projects

Salivary Gland Cancer - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Salivary Gland Cancer, H2 2016

Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Salivary Gland Cancer - Pipeline by Bayer AG, H2 2016

Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2016

Salivary Gland Cancer - Pipeline by Johnson & Johnson, H2 2016

Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2016

Salivary Gland Cancer - Pipeline by Merck & Co., Inc., H2 2016

Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2016

Salivary Gland Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Salivary Gland Cancer - Dormant Projects, H2 2016

Salivary Gland Cancer - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Salivary Gland Cancer, H2 2016

Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Ignyta, Inc.
  • Johnson & Johnson
  • Loxo Oncology, Inc.
  • Merck & Co., Inc.
  • Plexxikon Inc.
  • Taiwan Liposome Company, Ltd.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll